# A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

> **NCT05603156** · NA · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 46 (estimated)

## Conditions studied

- Ph+ ALL
- Bone Marrow Transplant
- Minimal Residual Disease

## Interventions

- **DRUG:** the usage of Olverembatinib combined with Inotuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT05603156
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-30
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2022-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603156, "A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05603156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*